Two sentences on a website. One FDA warning letter.

In August 2025 the FDA read the Hims & Hers website. It was not an inspection of a pharmacy, a facility, or a batch record. It was somebody at the agency reading marketing copy the same way a customer would.

On September 9 the agency sent a warning letter. It quoted two claims, verbatim, off the page. The first was the line telling shoppers the product contained the same active ingredient as Ozempic and Wegovy. The second described the ingredients as clinically proven.

Both sentences are, in a narrow chemical sense, defensible. That is exactly why they are dangerous, and why so many clinics have written some version of them without a second thought.

Why true was not good enough

The mechanism is a labeling statute, not an advertising one. Under the Federal Food, Drug, and Cosmetic Act a drug is misbranded if its labeling is false or misleading in any particular — and a separate provision extends that same test to the advertising and promotion of a compounded drug.

Read that second line again, because it is the whole ballgame. For a compounded product, your ad copy is not separate from the drug. Your ad copy is part of the drug's regulatory status. A marketing sentence can misbrand a medication.

The agency's reasoning on the Hims claims was short. Compounded drug products are not FDA-approved. Copy that draws an equivalence to an approved product implies the compounded version carries an approval it does not have. The claim does not have to be chemically wrong to be misleading — it only has to leave the reader believing something untrue.

The redline

Here is the same commercial idea, written two ways. The version on the left drew a federal letter. The version on the right sells the same benefit and says nothing the agency cited.

This was not a one-off

The Hims letter arrived inside a wave. The FDA sent roughly fifty letters that same week to companies marketing compounded GLP-1 products, part of a broader push against direct-to-consumer drug advertising announced days earlier.

Then it escalated. On March 3, 2026 the agency publicly released thirty more warning letters, this batch aimed squarely at telehealth companies and online wellness clinics making false or misleading claims about compounded GLP-1s. Days later, Novo Nordisk and Hims & Hers announced a partnership under which Hims sells branded, FDA-approved product and stops most of its compounded advertising.

Read the sequence honestly. The largest, best-resourced player in the category took two letters and then changed its business model. A single-location clinic does not have that option, which makes getting the copy right the first time the cheaper path by a wide margin.

Three rules that cover most of the exposure

1. Never draw an equivalence to a brand-name drug. Not the molecule, not the mechanism, not the results. The moment a reader could conclude your product is the approved one, the claim is misleading regardless of chemistry.
2. Never borrow a trial. "Clinically proven" and study statistics belong to the approved product that ran the study. Citing them for a compounded preparation transfers an approval you do not have.
3. State what the product actually is. Compounded, not FDA-approved, dispensed only on a prescription after a provider review, results vary. This is not a legal disclaimer buried in the footer — written well, it is the trust argument that separates you from the gray-market sellers.

None of this requires softer marketing. The Hims letter did not object to the offer, the price, the speed, or the convenience. It objected to two sentences that reached for someone else's approval.